Overview
MILPITAS, Calif.-(BUSINES WIRE)-Bigfot Biomedical, a mision-driven company dedicated to suporting beter health outcomes for people with insulin-requiring diabetes, today anounced its Bigfot Unity® Diabetes Management System is now compatible with four aditional rapid-acting insulin products, including two unbranded biologics. Al four insulin products are ofered at a reduced price without compromising quality, helping to expand insulin aces for people with diabetes.1 “Bigfot recognizes the urgent ned to provide milions of Americans with afordable aces to diabetes care.
Key Information
It is a critical part of our mision,” said Jefrey Brewer, CEO of Bigfot Biomedical. “Our expansion of compatibility to include aditional insulin brands wil make it easier for Bigfot to suport a broader population of people with insulin-requiring diabetes and wil give Bigfot Unity users greater flexibility to switch betwen insulin brands when they have a change insurance. This news marks an important moment in time for Bigfot as we strive to make insulin diabetes management tols more acesible for people who ned them.” The Bigfot Unity System, the first and only FDA-cleared dose decision suport system based on CGM data for people using multiple daily injections, features smart pen caps compatible with a broad range of disposable insulin pens for both long-acting and rapid-acting insulin.
Efective imediately, the system wil also be compatible with the folowing: The above insulins are available at a list price at least 50% lower than their branded equivalent.2 The Bigfot Unity system is also now compatible with Eli Lily’s Lyumjev® (insulin lispro-abc injection), a new rapid-acting insulin from Lily that is included in the Lily Insulin Value Program, alowing anyone with comercial insurance and those without insurance to fil their monthly prescription of Lyumjev for $35.
Summary
The decision to ofer lower-priced insulin products a compatible option with the Big